<DOC>
	<DOCNO>NCT02742259</DOCNO>
	<brief_summary>The Prostate Cancer Assay performance Celsee Diagnostics circulate tumor cell ( CTC ) analysis system validate patient diagnose metastatic prostate cancer . It demonstrate substantial performance equivalency CTC Assay predicate device .</brief_summary>
	<brief_title>Validation Prostate Cancer Assay - Beta+Pivotal</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>• Male age 18 year Be willing sign inform consent document indicate subject understands purpose procedure require study willing participate study Be willing/able adhere prohibition restriction specify protocol Eastern cooperative group ( ECOG ) performance status ≤2 Documented histologically confirm adenocarcinoma prostate Metastatic prostate cancer bone document positive bone scan image CRPC patient consider systemic therapy line therapy ( &gt; = 14 day prior treatment ) metastatic disease . Patient must evidence castrate resistant prostate cancer evidence confirm rise PSA ( per Prostate Cancer Working Group 2 [ PCWG2 ] criterion ) castrate serum testosterone level ( i.e . ≤ 50 mg/dl ) . • Subjects actively receive systemic therapy regimen , line therapy ( &lt; 14 day prior treatment ) Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement Active infection medical condition would make corticosteroid ( i.e . prednisone ) use contraindicate Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) Patients history hypertension allow provide blood pressure control antihypertensive treatment Severe hepatic impairment ( ChildPugh Class C ) History pituitary adrenal dysfunction ( note : use daily steroid exclude someone participate study ) Have poorly control diabetes ( HgB A1C ≥ 8 % ) Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule . Abnormal bone marrow function ( absolute neutrophil count [ ANC ] &lt; 1500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin &lt; 9 g/dL ) Abnormal liver function ( bilirubin &gt; upper limit normal [ ULN ] ; AST and/or ALT &gt; 1.5 x ULN concomitant alkaline phosphatase &gt; 2.5 x ULN ) Abnormal kidney function ( serum creatinine ≥ 2 x upper limit normal ) Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , unstable atrial fibrillation , New York Heart Association ( NYHA ) Class IIIIV heart disease History ventricular tachyarrhythmia within past 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>